IMNM Q2 2021 Earnings — Immunome, Inc. Revenue & Financial Results | Market Cap Arena

IMNMImmunome, Inc.

$2B

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$6M

Net Income

-$5M

EPS (Diluted)

$-0.46

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$4M

Stock-Based Comp.

$749,000

Balance Sheet

Total Assets

$64M

Total Liabilities

$4M

Stockholders' Equity

$61M

Cash & Equivalents

$60M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$6M	-$3M	-111.4%
Net Income	-$5M	-$3M	-93.4%